Appraisal specific projects
These are projects commissioned by NICE in relation to the appraisal of specific technologies under the Multiple Technology Appraisal (MTA) and Single Technology Appraisal (STA) programmes.
Alzheimer’s disease
TA111 Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine
ID4043 and ID6222 - Carer utilities in Alzheimer’s Disease
Age-related macular degeneration
TA155 Age-related macular degeneration – ranibizumab and pegaptanib
Ankylosing spondylitis
TA143 Ankylosing spondylitis – adalimumab, etanercept and infliximab
Breast cancer
ID20 Breast cancer – lapatinib
TA496 Breast cancer – ribociclib
Colorectal cancer
TA176 Colorectal cancer – cetuximab
Crohn's disease
TA187 Crohn's disease – adalimumab and infliximab
Diabetes
TA288 Diabetes – dapagliflozin
Lung Cancer
Lupus
Macular oedema
TA274 Macular oedema – bevacizumab
Myelodysplastic syndromes
TA128 Myelodysplastic syndromes – azacitidine
Osteoporosis
Prostate cancer
ID590 Prostate cancer – degarelix
Renal cell carcinoma
TA178 Renal cell carcinoma – bevacizumab, sorafenib, sunitinib and temsirolimus
Rheumatoid arthritis
TA130 Rheumatoid arthritis – adalimumab, etanercept and infliximab
Rheumatoid arthritis – adalimumab, etanercept and infliximab (sequential use)